Drug news
UK NICE in final guidance rejects Portrazza (necitumumab) to treat metastatic NSCLC.- Eli Lilly
The UK National Institute for Health and Care Excellence has published final guidance and rejected Portrazza (necitumumab) from Eli Lilly as a treatment for locally advanced or metastatic non small lung cancer in adults who had not been treated with chemotherapy.
Portrezza showed in trials about two months additional survival over chemotherapy but would cost £110 000 to £170 000 per quality adjusted life year and hence was not cost effective compared to combination chemotherapy (gemcitabine and cisplatin).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins